Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study

Journal of Bone and Mineral Research

Volumn 32, Issue 3, 2017, Pages 611-617

  Choi, Nam Kyong ^a,b,c   Solomon, Daniel H ^a   Tsacogianis, Theodore N ^a   Landon, Joan E ^a   Song, Hong Ji ^d   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Seoul National University   (South Korea)

^c Ewha Womans University   (South Korea)

^d Hallym University   (South Korea)

Author keywords

CARDIOVASCULAR DISEASE; DENOSUMAB; INFECTION; OSTEOPOROTIC FRACTURE; ZOLEDRONIC ACID

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPOROSIS; POPULATION RESEARCH; COMPARATIVE STUDY; INCIDENCE;

COHORT STUDIES; DENOSUMAB; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 85013131090     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3019     Document Type: Article

References (46)

1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756–65.
2. Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015; 26(12):2773–83.
3. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76.
4. Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag. 2012; 8:295–306.
5. Lewiecki EM. Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf. 2011; 3:79–91.
6. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014; 29(2):450–7.
7. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109(18):2175–80.
8. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106(10):1192–4.
9. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149(1):39–42.
10. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation. 2008; 117(3):411–20.
11. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009; 175(2):473–8.
12. Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab. 2015; 33(3):355–8.
13. Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone. 2014; 61:44–7.
14. Farrier AJ, Sanchez Franco LC, Shoaib A, et al. New anti-resorptives and antibody mediated anti-resorptive therapy. Bone Joint J. 2016; 98-B(2):160–5.
15. Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014; 85(1):3–5.
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809–22.
17. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010; 95(9):4380–7.
18. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007; 356(18):1895–6.
19. Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 2015; 67(6):1456–64.
20. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007; 60(4):397–409.
21. Patkar NM, Curtis JR, Teng GG, et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol. 2009 Mar;62(3):321–7, 327. e1–7.
22. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015; 128(6):653 e7–16.
23. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004; 148(1):99–104.
24. Choma NN, Griffin MR, Huang RL, et al. An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009; 18(11):1064–71.
25. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:100–28.
26. Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:129–40.
27. Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S. The validity of administrative data to identify hip fractures is high—a systematic review. J Clin Epidemiol. 2013; 66(3):278–85.
28. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992; 45(7):703–14.
29. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011; 64(7):749–59.
30. Wyss R, Girman CJ, LoCasale RJ, Brookhart AM, Sturmer T. Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiol Drug Saf. 2013; 22(1):77–85.
31. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009; 38(6):1228–34.
32. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016 Sep; 27(9):2835–44.
33. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013–22.
34. Huas D, Debiais F, Blotman F, et al. Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health. 2010; 10:26.
35. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008; 23(9):1435–41.
36. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(2 Suppl):S3–13.
37. Leslie WD, Lix LM, Yogendran MS. Validation of a case definition for osteoporosis disease surveillance. Osteoporos Int. 2011; 22(1):37–46.
38. Lix LM, Yogendran MS, Leslie WD, et al. Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol. 2008; 61(12):1250–60.
39. Goettsch WG, de Jong RB, Kramarz P, Herings RM. Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf. 2007; 16(2):166–72.
40. Maio V, Yuen E, Rabinowitz C, et al. Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy. J Health Serv Res Policy. 2005; 10(4):232–8.
41. Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW. A RANKL wrinkle: denosumab-induced hypocalcemia. J Med Toxicol. 2016 Sep; 12(3):305–8.
42. Kreutle V, Blum C, Meier C, et al. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. Swiss Med Wkly. 2014; 144:w13979.
43. Solzbach U, Kitterer HR, Haas H. Reversible congestive heart failure in severe hypocalcemia. Herz. 2010; 35(7):507–10.
44. Jackson T, Kondic J, Seebeck J. QT-prolonging effects of monoclonal antibody drugs in humans: a systematic review of two literature and a public adverse event database. Int J Clin Pharmacol Ther. 2015; 53(9):705–11.
45. Oiwa H, Mokuda S. Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease. Eur J Rheumatol. 2016 Sep; 3(3):144–5.
46. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015; 11(7):437–41.